The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1464014
A Hyper-Acute Immune Hemolytic Anemia Induced by Contrast Medium Was Successfully Treated With Eculizumab -A Case Report
Provisionally accepted- 1 University Clinic for Anesthesiology and Intensive Care Medicine, University Hospital Tuebingen, Tübingen, Germany
- 2 Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany
- 3 Department of Thoracic and Cardiovascular Surgery, University Hospital Saarland, Homburg/Saar, Germany
- 4 Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Contrast medium is frequently associated with allergic reaction and kidney dysfunction. However, contrast media can induce hemolytic anemia with a broad spectrum of hemolytic manifestation. We report of a 38-year-old patient with very severe immune hemolytic anemia after application of Iomeprol due to a CT thorax/abdomen. In this case report, we illustrate the diagnostics and treatment of a life-threatening hemolytic anemia induced by contrast medium that was successfully treated with eculizumab.
Keywords: Drug-induced hemolysis, contrast medium-induced hemolysis, Eculizumab, hemolytic anemia, immunological hemolysis
Received: 21 Jul 2024; Accepted: 20 Jan 2025.
Copyright: © 2025 Hermann, Althaus, Mustafi, Mayer, Rosenberger, Häberle and Bernard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Helene Anna Häberle, University Clinic for Anesthesiology and Intensive Care Medicine, University Hospital Tuebingen, Tübingen, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.